Beyond that, an augmented CD86+CXCR4lo CLL subpopulation in peripheral blood was an independent predictive marker for shorter time to first treatment, which further supports our hypothesis that CD86 indicates the magnitude of CLL cells cycling through proliferation centers, and hence, is associated with intraclonal diversification. This evidence concerns the gene CD86 and B-cell chronic lymphocytic leukemia.